Effect of Violence on Healthcare

Deliberate, calculated attacks on healthcare facilities have become a routine weapon of war. These assaults kill both patients and health workers, and they devastate already vulnerable health systems. Not to mention they violate the Geneva Conventions.

In 2017, there were at least 701 attacks on hospitals, health workers, patients, and ambulances in 23 countries in conflict around the world. More than 101 health workers and 293 patients and others are reported to have died as a result of these attacks. The 2017 report, compiled by the Safeguarding Health in Conflict Coalition, only includes events that occurred in the context of armed conflicts or situations of severe political volatility.
Continue reading “Effect of Violence on Healthcare”

Brexit and the delay in the supply of medicines

Earlier this year, the Brexit Health Alliance published a paper calling on both the UK and EU to put patients first.

It warned that unless a deal can be reached, medicines and medical technologies could be delayed or, in extreme cases, become unavailable to patients.

The Alliance is concerned that if a decision can’t be reached regarding the future co-operation between the UK and the EU on the regulation and trade of medicines and medical devices that up to 120,000 prostate cancer patients throughout Europe could be affected.

Another area at risk is the future of research into new medicines and medical technologies. Without a plan in place, UK and EU patients could lose out on access to the best treatments and medical devices.

Are you concerned about the impact of Brexit? 
You can find below what the M3 Global Research community answered to this question.

Let us hear your opinion on this by signing up to receive the Monthly Pulse via email and to take part in paid medical studies.

 

Technology investment in the healthcare sector

Our first monthly Pulse of 2018 asked the M3 Global Research community their opinions on technology investment in healthcare. The healthcare sector has experienced dramatic changes over the last 25 years and will likely continue to change and evolve in the immediate future. Technology is already powering new models of care and disrupting traditional ideas about care provision. However, the level of investment will become a key driver in the speed of delivery. For this Pulse survey we asked healthcare professionals which areas of potential technology investment they think would have the most impact patients over the next five years. Participants could choose up to three of the following:

  1. Preventative medicine (home test kits, measures for disease prevention and identification of risk factors)
  2. Self-diagnosis (recognising or identifying medical conditions for oneself using online resources)
  3. Telemedicine (online or telephone consultations with HCPs without face-to-face contact)
  4. Social prescribing (a means of enabling primary care professionals to refer patients to a range of local, non-clinical services)
  5. Self-care (actions that individuals take for themselves in order to protect, maintain and improve their health or wellbeing)
  6. Care navigation (using signposting and information to help patients and their carers identify their treatment and care options)
  7. Patient access to online health records (patients can access, electronically, their own records from all primary and secondary care interactions)
  8. Other

January’s Pulse revealed that the majority of respondents in Europe, Canada, and the US believe that telemedicine, with 2,752 votes, is the area of technological investment that will most improve patient care over the next five years.  This might include Skype consultations, or digital clinics, and would be particularly useful in improving access to care in remote areas or for specialist treatment. Preventive medicine followed as the next most popular option, with 2,495 votes, and was particularly popular in the United States. Preventative medicine is seen to be a way of reducing healthcare costs, and also improve efficacy of treatments by early diagnosis, and so might include the  development of home testing kits, for example. Social prescribing was deemed to have the least potential impact, with only 485 votes, but this could be because its application is less well understood outside the UK, where it is quickly gaining traction. In the UK, primary care clinicians are able to refer patients to a range of local, non-clinical services, often provided by the voluntary and community sector, thus reducing costs for the NHS.

In Europe specifically, results broadly reflected the global findings, with 2,710 professionals surveyed in UK, Germany, France, Spain and Italy choosing telemedicine as the area of technological investment that they thought would most improve patient care over the next five years. Preventive medicine followed, with 2,436 votes. Social prescribing was the option with the least votes, with 485.

healthcare sector

Interestingly, in the USA results were different. Preventive medicine was chosen as the area of technological investment that will most improve patient care over the next five years, with 1,136. Telemedicine came in second, with 517 votes. Self-diagnosis apps were deemed to have the least potential impact, with only 86 votes.

Technology investment

By registering with M3 Global Research you will receive the monthly Pulse straight to your inbox so you can give your opinion about topical healthcare-related issues and compare your thoughts with those of your colleagues around the world.

Take Part in a Melanoma Patient Outcome Study

Patient outcome studies are becoming increasingly important as they provide a truly in-depth analysis of the chosen subject matter as well as benefits to the participants.

We are pleased to announce that we will have a patient outcome study regarding melanoma very soon in the United States and the incentive will be up to $600We are looking for oncologists and dermatologists practicing in the United States that specialize in melanoma treatments to participate in this exciting study.

This multi-stage study involves both treaters and those receiving the treatment providing an in-depth understanding of clinical, behavioral, and payer practice in distinct areas. All data is strictly confidential.

The data collected from this study will be used to ensure the best possible treatment guidelines. Furthermore, it will be published in peer-review journals and presented at key conferences.

If you are not a member and you wish to participate in this study, register below by clicking here.

If you are already a member of our panel and you wish to reserve your place, please let us know: M3_US_support@eu.m3.com

Read the interview with a melanoma specialist from the United States in the section “Our Doctors talk”.

black ribbons on hands, for Skin cancer awareness, Melanoma Awareness,Narcolepsy Awareness and Mourning